Comparative Pharmacology
Head-to-head clinical analysis: DIANEAL PD 1 W DEXTROSE 1 5 IN PLASTIC CONTAINER versus INPERSOL LC LM W DEXTROSE 3 5 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: DIANEAL PD 1 W DEXTROSE 1 5 IN PLASTIC CONTAINER versus INPERSOL LC LM W DEXTROSE 3 5 IN PLASTIC CONTAINER.
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER vs INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dianeal PD-1 with Dextrose 1.5% is a peritoneal dialysis solution that uses dextrose as an osmotic agent to create a concentration gradient across the peritoneal membrane, facilitating the removal of waste products (e.g., urea, creatinine) and excess fluid from the blood into the peritoneal cavity via diffusion and ultrafiltration.
Inpersol-LC/LM with 3.5% dextrose is a peritoneal dialysis solution that provides osmotic ultrafiltration via dextrose, removing waste products and excess fluid from the blood across the peritoneal membrane. The low calcium (LC) and low magnesium (LM) formulations adjust electrolyte concentrations to manage imbalances.
2 L intraperitoneally via continuous ambulatory peritoneal dialysis (CAPD) four times daily, with dwell times of 4-6 hours each. For automated peritoneal dialysis (APD), 2 L per cycle with 4-5 cycles overnight.
Intraperitoneal administration: 2 to 2.5 liters per exchange, 4 to 5 exchanges per day, as prescribed by physician based on peritoneal equilibration test.
None Documented
None Documented
Dextrose half-life is approximately 1-2 hours in normal individuals; with peritoneal dialysis, elimination is governed by dialysate dwell time and peritoneal transport characteristics, typically 4-6 hours for complete absorption.
Not applicable; dextrose is continuously infused and removed; the half-life of intraperitoneal dextrose is approximately 1-2 hours due to rapid absorption and metabolism, with clinically relevant hyperglycemia managed by insulin.
Renal: dialysis (peritoneal) accounts for >95% of dextrose elimination; minimal renal excretion (<5% unchanged dextrose). Biliary/fecal: negligible.
Renal (via peritoneal dialysis effluent); approximately 60-70% of administered dextrose is absorbed and metabolized, with the remainder removed in dialysate; no significant biliary/fecal elimination.
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution